{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:55:06Z","timestamp":1774076106617,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Administration of tuberculosis (TB) vaccines in participants with previous or current pulmonary TB may have the potential for causing harmful postvaccination immunologic (Koch-type) reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the safety and immunogenicity of three dose levels of the AERAS-402 live, replication-deficient adenovirus 35\u2013vectored TB candidate vaccine, containing three mycobacterial antigens, in individuals with current or previous pulmonary TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a phase II randomized, placebo-controlled, double-blinded dose-escalation study in an HIV-negative adult South African cohort (n\u2009=\u200972) with active pulmonary TB (on treatment for 1\u20134 mo) or pulmonary TB treated at least 12 months before study entry and considered cured. Safety endpoints included clinical assessment, flow volume curves, diffusing capacity of the lung for carbon monoxide, pulse oximetry, chest radiograph, and high-resolution thoracic computerized tomography scans. Cytokine expression by CD4 and CD8 T cells, after stimulation with Ag85A, Ag85B, and TB10.4 peptide pools, was examined by intracellular cytokine staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>No apparent temporal or dose-related changes in clinical status (specifically acute, Koch phenomenon\u2013like reactions), lung function, or radiology attributable to vaccine were observed. Injection site reactions were mild or moderate. Hematuria (by dipstick only) occurred in 25 (41%) of 61 AERAS-402 recipients and 3 (27%) of 11 placebo recipients, although no gross hematuria was reported. AERAS-402 induced robust CD8+ and moderate CD4+ T-cell responses, mainly to Ag85B in both vaccine groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of the AERAS-402 candidate TB vaccine to participants with current or previous pulmonary TB induced a robust immune response and is not associated with clinically significant pulmonary complications.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 02414828) and in the South African National Clinical Trials Register (www.sanctr.gov.za DOH 27-0808-2060).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201603-0654oc","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T09:04:03Z","timestamp":1488791043000},"page":"1171-1180","source":"Crossref","is-referenced-by-count":33,"title":["Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial"],"prefix":"10.1093","volume":"195","author":[{"given":"Richard N.","family":"van Zyl-Smit","sequence":"first","affiliation":[{"name":"University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliasgar","family":"Esmail","sequence":"additional","affiliation":[{"name":"University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Bateman","sequence":"additional","affiliation":[{"name":"University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[{"name":"University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[{"name":"UCLA Medical Centre, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"van Rikxoort","sequence":"additional","affiliation":[{"name":"Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., a Janssen Pharmaceutical company of Johnson & Johnson, Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Pau","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., a Janssen Pharmaceutical company of Johnson & Johnson, Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald C.","family":"Sadoff","sequence":"additional","affiliation":[{"name":"Crucell Holland B.V., a Janssen Pharmaceutical company of Johnson & Johnson, Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bruce","family":"McClain","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret Ann","family":"Snowden","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Benko","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hokey","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn Tucker","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Graves","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadritdin","family":"Ishmukhamedov","sequence":"additional","affiliation":[{"name":"Aeras, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M. N.","family":"Kagina","sequence":"additional","affiliation":[{"name":"South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, and"},{"name":"Vaccines for Africa Initiative, Division of Medical Microbiology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Abel","sequence":"additional","affiliation":[{"name":"South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, and"},{"name":"Singapore Immunology Network, Agency for Science, Technology and Research, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem A.","family":"Hanekom","sequence":"additional","affiliation":[{"name":"South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Scriba","sequence":"additional","affiliation":[{"name":"South African TB Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-5849","authenticated-orcid":false,"given":"Eric D.","family":"Bateman","sequence":"additional","affiliation":[{"name":"University of Cape Town Lung Institute, Division of Pulmonology, Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"key":"2026032023392332100_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","article-title":"Prospects for tuberculosis elimination","volume":"34","author":"Dye","year":"2013","journal-title":"Annu Rev Public Health"},{"key":"2026032023392332100_bib2","author":"World Health Organization Executive Board"},{"key":"2026032023392332100_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/imr.12270","article-title":"Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool","volume":"264","author":"Karp","year":"2015","journal-title":"Immunol Rev"},{"key":"2026032023392332100_bib4","first-page":"239","article-title":"The Koch phenomenon and the immunopathology of tuberculosis","volume":"215","author":"Rook","year":"1996","journal-title":"Curr Top Microbiol Immunol"},{"key":"2026032023392332100_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026032023392332100_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/imr.12249","article-title":"Cytokine and lipid mediator networks in tuberculosis","volume":"264","author":"Mayer-Barber","year":"2015","journal-title":"Immunol Rev"},{"key":"2026032023392332100_bib7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1099\/vir.0.81956-0","article-title":"Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells","volume":"87","author":"Havenga","year":"2006","journal-title":"J Gen Virol"},{"key":"2026032023392332100_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrmicro1419","article-title":"Advances in tuberculosis vaccine strategies","volume":"4","author":"Skeiky","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"2026032023392332100_bib9","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Radosevic","year":"2007","journal-title":"Infect Immun"},{"key":"2026032023392332100_bib10","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","article-title":"Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge","volume":"193","author":"Darrah","year":"2014","journal-title":"J Immunol"},{"key":"2026032023392332100_bib11","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023392332100_bib12","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"Hoft","year":"2012","journal-title":"Vaccine"},{"key":"2026032023392332100_bib13","author":"Bateman"},{"key":"2026032023392332100_bib14","author":"Bennett"},{"key":"2026032023392332100_bib15","author":"van Zyl-Smit"},{"key":"2026032023392332100_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026032023392332100_bib17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"2026032023392332100_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1183\/09031936.05.00034905","article-title":"Standardisation of the single-breath determination of carbon monoxide uptake in the lung","volume":"26","author":"Macintyre","year":"2005","journal-title":"Eur Respir J"},{"key":"2026032023392332100_bib19","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts &gt;350 cells\/mm(3)","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"key":"2026032023392332100_bib20","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"2026032023392332100_bib21","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2015.03.070","article-title":"A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants","volume":"33","author":"Tameris","year":"2015","journal-title":"Vaccine"},{"key":"2026032023392332100_bib22","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1182\/blood-2002-11-3577","article-title":"Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines","volume":"101","author":"Geginat","year":"2003","journal-title":"Blood"},{"key":"2026032023392332100_bib23","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.4049\/jimmunol.175.9.5895","article-title":"Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets","volume":"175","author":"Willinger","year":"2005","journal-title":"J Immunol"},{"key":"2026032023392332100_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"2026032023392332100_bib25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1378\/chest.117.3.752","article-title":"Evaluation of diffusing capacity in patients with a restrictive lung disease","volume":"117","author":"Stam","year":"2000","journal-title":"Chest"},{"key":"2026032023392332100_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.200210-1245OC","article-title":"Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends","volume":"168","author":"Latsi","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023392332100_bib27","doi-asserted-by":"crossref","first-page":"c2843","DOI":"10.1136\/bmj.c2843","article-title":"How to investigate a patient with suspected interstitial lung disease","volume":"340","author":"Dempsey","year":"2010","journal-title":"BMJ"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/195\/9\/1171\/67142413\/ajrccm_195_9_1171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/195\/9\/1171\/67142413\/ajrccm_195_9_1171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:39:52Z","timestamp":1774064392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/195\/9\/1171\/8500142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,5,1]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201603-0654oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5]]},"published":{"date-parts":[[2017,5,1]]}}}